| Preview | Issue Date | Title | Author(s) |
| 2015 | Adequacy of high-dose cefepime regimen in febrile neutropenic patients with hematological malignancies | Sime, F.B.; Roberts, M.S.; Tiong, I.S.; Gardner, J.H.; Lehman, S.; Peake, S.L.; Hahn, U.; Warner, M.S.; Roberts, J.A. |
| 2014 | Altered pharmacokinetics of piperacillin in febrile neutropenic patients with hematological malignancy | Sime, F.B.; Roberts, M.S.; Warner, M.S.; Hahn, U.; Robertson, T.A.; Yeend, S.; Phay, A.; Lehman, S.; Lipman, J.; Peake, S.L.; Roberts, J.A. |
| 2008 | Bench-to-bedside review: the evaluation of complex interventions in critical care | Delaney, A.; Angus, D.C.; Bellomo, R.; Cameron, P.; Cooper, D.J.; Finfer, S.; Harrison, D.A.; Huang, D.T.; Myburgh, J.A.; Peake, S.L.; Reade, M.C.; Webb, S.A.R.; Yealy, D.M. |
| 2016 | Calorie delivery and clinical outcomes in the critically ill: a systematic review and meta-analysis | Parikh, H.G.; Miller, A.; Chapman, M.; Moran, J.L.; Peake, S.L. |
| 2015 | Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial | Sime, F.B.; Roberts, M.S.; Tiong, I.S.; Gardner, J.H.; Lehman, S.; Peake, S.L.; Hahn, U.; Warner, M.S.; Roberts, J.A. |
| 2018 | Energy-dense versus routine enteral nutrition in the critically ill | Chapman, M.; Peake, S.L.; Bellomo, R.; Davies, A.; Deane, A.; Horowitz, M.; Hurford, S.; Lange, K.; Little, L.; Mackle, D.; O'Connor, S.; Presneill, J.; Ridley, E.; Williams, P.; Young, P. |
| 2022 | Gastrointestinal dysfunction during enteral nutrition delivery in ICU patients: Risk factors, natural history and clinical implications. A post-hoc analysis of the TARGET trial | Murthy, T.A.; Chapple, L.-A.S.; Lange, K.; Marathe, C.S.; Horowitz, M.; Peake, S.L.; Chapman, M.J. |
| 2018 | Nutrition therapy in Australia and New Zealand Intensive Care Units: An international comparison study | Ridley, E.J.; Peake, S.L.; Jarvis, M.; Deane, A.M.; Lange, K.; Davies, A.R.; Chapman, M.; Heyland, D. |
| 2022 | Optimising antifungal prophylaxis in allogeneic stem cell transplantation - a cohort study of two different approaches | Selby, P.R.; Warner, M.S.; Peake, S.L.; Bardy, P.; Hiwase, D.; Singhal, D.; Beligaswatte, A.; Hahn, U.; Roberts, J.A.; Yeung, D.; Shakib, S. |
| 2020 | Outcomes six-months after 100% or 70% of enteral calorie requirements during critical illness (TARGET): a randomized controlled trial | Deane, A.M.; Little, L.; Bellomo, R.; Chapman, M.J.; Davies, A.R.; Ferrie, S.; Horowitz, M.; Hurford, S.; Lange, K.; Litton, E.; Mackle, D.; O'Connor, S.; Parker, J.; Peake, S.L.; Presneill, J.J.; Ridley, E.J.; Singh, V.; van Haren, F.; Williams, P.; Young, P.; et al. |
| 2019 | Plasma and interstitial fluid population pharmacokinetics of vancomycin in critically ill patients with sepsis | Abraham, J.; Sinnollareddy, M.G.; Roberts, M.S.; Williams, P.; Peake, S.L.; Lipman, J.; Roberts, J.A. |
| 2023 | Population Pharmacokinetics of Ganciclovir in Allogeneic Hematopoietic Stem Cell Transplant Patients | Selby, P.R.; Heffernan, A.J.; Yeung, D.; Warner, M.S.; Peake, S.L.; Hahn, U.; Wallis, S.C.; Mcwhinney, B.; Ungerer, J.P.J.; Shakib, S.; Roberts, J.A. |
| 2021 | The cost-effectiveness of early goal-directed therapy: an economic evaluation alongside the ARISE trial | Higgins, A.M.; Peake, S.L.; Ao, R.B.; Ao, D.J.C.; Delaney, A.; Howe, B.D.; Nichol, A.D.; Webb, S.A.; Williams, P.J.; Harris, A.H. |
| 2021 | The effect of renal replacement therapy and antibiotic dose on antibiotic concentrations in critically ill patients: data from the multinational Sampling Antibiotics in Renal Replacement Therapy Study | Roberts, J.A.; Joynt, G.; Lee, A.; Choi, G.; Bellomo, R.; Kanji, S.; Mudaliar, M.Y.; Peake, S.L.; Stephens, D.; Taccone, F.S.; Ulldemolins, M.; Valkonen, M.M.; Agbeve, J.; Baptista, J.P.; Bekos, V.; Boidin, C.; Brinkmann, A.; Buizen, L.; Castro, P.; Cole, C.L.; et al. |
| 2021 | Use of a high-protein enteral nutrition formula to increase protein delivery to critically ill patients: a randomized, blinded, parallel-group, feasibility trial | Chapple, L.-A.S.; Summers, M.J.; Bellomo, R.; Chapman, M.J.; Davies, A.R.; Ferrie, S.; Finnis, M.E.; Hurford, S.; Lange, K.; Little, L.; O'Connor, S.N.; Peake, S.L.; Ridley, E.J.; Young, P.J.; Williams, P.J.; Deane, A.M.; TARGET Investigator Collaborative and the ANZICS Clinical Trials Group, |
